Clinical study on 3D-CRT combined with nimotuzumab and chemotherapy in the treatment of stages Ⅲ-ⅣA nasopharyngeal carcinoma
TANG Wu-bing, YANG Wen, CAO Yang, WU Chu-rong, PAN Xing-xi, LIU Zhen-heng, ZHANG Yong-sheng
Published 2012-05-01
Cite as Chin J Prim Med Pharm, 2012,19(09): 1293-1295. DOI: 10.3760/cma.j.issn.1008-6706.2012.09.006
Abstract
Objective To explore the effect and safety of three-dimensional conformal radiotherapy (3D-CRT) m combination with nimotuzumab and chemotherapy in treatment patients with locoregionally advanced nasopharyngeal carcinoma.Methods 60 patients with stages Ⅲ-ⅣA nasopharyngeal carcinoma were enrolled.All patients were treated with 3D-CRT and concurrent and sequential chemotherapy by paclitaxel and eisplatin and given nimotuzumab 100mg i.v.weekly for 6 ~ 7 weeks before radiotherapy.Results After two months,the complete response rates(CR) of nasopharyngeal carcinoma and cervix lymph nodes were 98.3%,96.7% respectively,l-year locoregional control and distant metastasis-free survival rates were 100%,96.7% in 38 patients.2-year,3-year locoregional control and distant metastasis-free survival rates were 100% in 16 patients and 8 patients.The major side effects included oral mucositis,actinodermatitis,neutropenia,nausea,vomiting,and fatigue.Grade 3 acute oral mucositis often occured.No skin rash or allergic toxicities appeared.All the effects were tolerable.Conclusion 3D-CRT combined with nimotuzumab and peclitaxel and cisplatin chemotherapy may improve the complete response rate and locoregional control and distant metastasis-free survival rate on locoregionally advanced nasopharyngeal carcinoma,with mild to moderate side effects.
Key words:
Nasopharyngeal neoplasms; Radiotherapy conformal; Chemotherapy
Contributor Information
TANG Wu-bing
Department of Oncology,Nanhai Hospital Affiliated to Nanfang Medical University,Foshan,Guangdong 528200,China
YANG Wen
Department of Oncology,Nanhai Hospital Affiliated to Nanfang Medical University,Foshan,Guangdong 528200,China
CAO Yang
Department of Oncology,Nanhai Hospital Affiliated to Nanfang Medical University,Foshan,Guangdong 528200,China
WU Chu-rong
Department of Oncology,Nanhai Hospital Affiliated to Nanfang Medical University,Foshan,Guangdong 528200,China
PAN Xing-xi
Department of Oncology,Nanhai Hospital Affiliated to Nanfang Medical University,Foshan,Guangdong 528200,China
LIU Zhen-heng
Department of Oncology,Nanhai Hospital Affiliated to Nanfang Medical University,Foshan,Guangdong 528200,China
ZHANG Yong-sheng
Department of Oncology,Nanhai Hospital Affiliated to Nanfang Medical University,Foshan,Guangdong 528200,China